Comments on: Biogen wants Facet http://www.fusioninvesting.com/2009/09/biogen-wants-facet/ Fusing Fundamental and Technical Analysis with lashings of Behavioural Finance. Investing in Australia and North America. Thu, 02 Feb 2012 06:57:27 +0000 hourly 1 http://wordpress.org/?v=3.2 By: Dean Morel http://www.fusioninvesting.com/2009/09/biogen-wants-facet/comment-page-1/#comment-1221 Dean Morel Sun, 27 Sep 2009 09:44:57 +0000 http://www.fusioninvesting.com/?p=3274#comment-1221 I sold our Facet shares on Friday; hopefully, for those still holding that means Biogen will soon up their offer. I sold our Facet shares on Friday; hopefully, for those still holding that means Biogen will soon up their offer.

]]> By: Dean Morel http://www.fusioninvesting.com/2009/09/biogen-wants-facet/comment-page-1/#comment-1159 Dean Morel Tue, 08 Sep 2009 13:37:22 +0000 http://www.fusioninvesting.com/?p=3274#comment-1159 "Facet said investors have not taken into account the potential value of daclizumab, the company's new treatment for multiple sclerosis. Chief Executive Faheem Hasnain said Biogen Idec made its offer now because it recognizes the potential value of the drug. In addition, Facet said Biogen Idec's proposal is less than the value of the company's cash and marketable securities, which it pegged at $371.1 million, or $15.11 a share." CBS MarketWatch Facet share price $16.05 “Facet said investors have not taken into account the potential value of daclizumab, the company’s new treatment for multiple sclerosis. Chief Executive Faheem Hasnain said Biogen Idec made its offer now because it recognizes the potential value of the drug.

In addition, Facet said Biogen Idec’s proposal is less than the value of the company’s cash and marketable securities, which it pegged at $371.1 million, or $15.11 a share.”
CBS MarketWatch
Facet share price $16.05

]]>